In a report released today, Sam Slutsky from LifeSci Capital maintained a Buy rating on Palvella Therapeutics, with a price target of $90.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sam Slutsky has given his Buy rating due to a combination of factors related to Palvella Therapeutics’ innovative approach in addressing venous malformations (VMs). The company has developed QTORIN 3.9% rapamycin, a high-concentration topical gel designed for effective dermal penetration with minimal systemic absorption. This formulation is strategically positioned to meet the significant unmet needs in VMs, particularly those with a cutaneous component, by delivering therapeutic levels directly to the affected areas.
Furthermore, the recent publication by Teng et al. highlights the limitations of current sirolimus products due to their low concentration and high systemic absorption, which often result in adverse events. Palvella’s QTORIN 3.9% rapamycin addresses these issues by achieving approximately 1000-fold higher skin concentrations compared to oral dosing, offering a more consistent and effective treatment option. The ongoing Phase 2 TOIVA trial, with results expected in December 2025, further supports the potential of QTORIN as a promising solution, reinforcing Slutsky’s positive outlook on the company’s stock.
According to TipRanks, Slutsky is a 5-star analyst with an average return of 13.6% and a 41.31% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Palvella Therapeutics, and Cogent Biosciences.
In another report released yesterday, H.C. Wainwright also maintained a Buy rating on the stock with a $75.00 price target.